AbbVie Is Up 10% in a Month to a 52-Week High: Is There “More Room for Multiple Expansion”?
AbbVie's stock rose 10% in a month to a 52-week high, driven by investor rotation into big drugmakers. Q3 results beat estimates, with Skyrizi sales exceeding forecasts. The company raised 2026 adjusted EPS guidance to $13.95-$13.99. Analysts expect EPS growth from $10.00 in 2025 to $18.10 in 2028. The stock's forward P/E is now above its five-year average.
How this was made
The 30-second read
Why it matters
The combination of a modest EPS guidance downgrade and a positive Phase 3 result creates a nuanced market reaction, likely leading to short‑term volatility.
Market read
AbbVie’s mixed news may cause short‑term price swings, while the broader pharma sector could benefit from rotation.
What to watch
Potential competition from J&J's Tremfya and upcoming 2027 sales ramp for Skyrizi.
Background
AbbVie’s stock rose 10% in a month as investors rotated from AI to large drugmakers; the article details recent guidance cut and clinical trial outcomes.
Ticker impact
AbbVie lowered its 2026 adjusted EPS guidance and reported Phase 3 trial success for lutikizumab with FDA approval for at‑home Skyrizi.
mixed direction as trial success may offset guidance downgrade pressure
Guidance cut typically drags price, while breakthrough trial data and approval can drive upside; market will weigh both.
Market effects
Big‑pharma rotation may lift other drugmakers, especially those with pipeline news.
U.S. healthcare sector sees modest bullish bias.
Limited to pharma investors; no broad macro effect.
Counterpoint
The guidance cut signals deeper earnings pressure; trial news may be over‑hyped.
Key entities
- companyAbbVie
U.S. pharmaceutical company reporting guidance and trial news.
